ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Acadia Pharma (ACAD) Tops Q4 EPS by 5c
February 26, 2019 4:13 PM ESTAcadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.50), $0.05 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $59.6 million versus the consensus estimate of $59.46 million.
Our team successfully executed on all three of our strategic pillars in 2018. We grew NUPLAZID in Parkinsons... More
